Sandoz Canada Joins Humira Biosimilar Race With Hyrimoz Approval
Enoxaparin Biosimilar Inclunox Also Approved By Health Canada
Sandoz Canada is looking to roll out its biosimilar to AbbVie’s Humira early in the new year following approval from Health Canada, with multiple other adalimumab candidates also reportedly approved.
You may also be interested in...
Sandoz has confirmed the launch of its Hyrimoz biosimilar rival to Humira in Canada, with other biosimilars firms having also set their sights on a mid-February launch.
In the month ahead, Amarin is likely to reveal the latest on its plans to petition the US Supreme Court over generic versions of Vascepa, while biosimilar competition to Humira is set to arrive and the bulk of fourth-quarter and year-end financial results will emerge.
Canada’s Valeo Pharma says it intends to pursue discussions for the inclusion of its Redesca enoxaparin biosimilar on all other provincial formularies, after being backed for listing on the Quebec public health plan.